Unlocking the Economic Potential of Dementia Research: A Call for Increased Investment

By HEOR Staff Writer

July 17, 2023

UK government funding for dementia research has declined from its peak in 2018-2019. Despite this, the field shows high potential for research in the coming years. By 2040, over 1.2 million people in the UK are expected to have dementia, a 30% increase from 2022. The economic benefits of dementia research can be measured through an economic impact assessment (EIA), which considers various dimensions of dementia research. The report also highlights the significant impact of COVID-19 on people with dementia.

  • Dementia research in 2019/20 generated 7,353 full-time equivalent (FTE) jobs and contributed over £529 million in gross value added (GVA) to the UK economy.
  • Directly, dementia research supported 2,607 FTE jobs, including 2,059 research/scientific and technical roles and 548 administrative roles, contributing over £276 million in GVA.
  • Indirectly, dementia research supported and created 4,746 FTE jobs, contributing over £252 million in GVA.
  • Full-time salaries in dementia R&D and administration are, on average, 41% and 24.5% higher respectively than the average salary across all jobs in a region.

The risk of developing dementia or becoming an informal carer for a person with dementia is high. The study found that every £1 invested in dementia research generated £2.59 of economic benefit in the UK during 2019/20, and this is expected to increase to £2.91 on average in the next 20 years. Thus, increased investment in dementia research could improve the lives of those affected by dementia and create long-term economic growth in the UK.

Reference url

Recent Posts

Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programm...

By João L. Carapinha

December 4, 2025

How will the EU Health Technology Assessment framework evolve in 2026 to improve clinical evaluations for cancer treatments and advanced therapies? The EU Health Technology Assessment (HTA) initiative coordinates standardized reviews of medicines and devices across Member States, thereby boosting...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
What does the latest WHO guideline reveal about GLP-1 obesity therapies, as released in December 2025? This landmark document establishes the first global standards for integrating glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 dual agonists into chronic obesity management, treat...
Strengthening EU Pharmaceutical Supply Security Through the Critical Medicines Act

By HEOR Staff Writer

December 3, 2025

Enhancing EU Supply Security for Essential Pharmaceuticals The EU's Critical Medicines Act proposal is a key initiative to strengthen EU pharmaceutical supply security amid ongoing shortages of vital drugs like antibiotics,...